Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV002512051 | SCV002821142 | pathogenic | not provided | 2024-01-01 | criteria provided, single submitter | clinical testing | ARSA: PM3:Very Strong, PM2, PS3:Supporting |
Invitae | RCV003500499 | SCV004300062 | pathogenic | Metachromatic leukodystrophy | 2023-12-13 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 379 of the ARSA protein (p.Pro379Leu). This variant is present in population databases (rs74315478, gnomAD 0.0009%). This missense change has been observed in individual(s) with late infantile metachromatic leukodystrophy, and is commonly reported in individuals of Habbanite Jewish ancestry (PMID: 7749412). It is commonly reported in individuals of Jewish ancestry (PMID: 7749412). This variant is also known as P377L. ClinVar contains an entry for this variant (Variation ID: 3083). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSA protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects ARSA function (PMID: 7749412). For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000003229 | SCV000023387 | pathogenic | Arylsulfatase a pseudodeficiency, severe | 1994-01-01 | no assertion criteria provided | literature only |